{
    "nct_id": "NCT03832361",
    "official_title": "A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer",
    "inclusion_criteria": "* Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endometrial cancer\n* Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Grade 2 or Grade 3 endometrial adenocarcinoma, Carcinosarcoma with high grade serous or Grade 2/3 endometrioid components, or clear cell carcinoma (Pure or Mixed).\n* Have measurable disease\n* FRα-positive tumor expression as defined in the protocol\n* Have at least one \"target lesion\" to be used to assess response as defined by RECIST v1.1\n* Patients must have received prior treatment with ≤ 3 prior lines of therapy for recurrent disease; hormonal agents are not considered a line of therapy; prior treatment with folate receptor-targeting investigational agents is not allowed\n* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Time from prior therapy: Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter; Radiotherapy: wide-field radiotherapy completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment\n* Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy\n* Patients must have adequate hematologic, liver and kidney function as defined in the protocol\n* Women of child bearing potential (WCBP), must agree to use effective contraceptive methods during study treatment and for at least twelve weeks after the last dose of IMGN853\n* WCBP must have a negative pregnancy test within 4 days prior to the first dose of study treatment\n* At time of initial surgery, patient may have either been optimally or suboptimally debulked\n* Have signed the informed consent form, and willing to adhere to the study visit schedule and other protocol requirements\n* ≥ 18 years of age\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Active or chronic corneal disorder\n* Serious concurrent illness or clinically-relevant active infection as defined in the protocol\n* Clinically-significant cardiac disease such as recent myocardial infarction (≤ 6 months prior to day 1), unstable angina pectoris, uncontrolled congestive heart failure, uncontrolled hypertension, prior history of hypertensive crisis or hypertensive encephalopathy, uncontrolled cardiac arrhythmias, clinically-significant vascular disease, severe aortic stenosis, clinically significant peripheral vascular disease, or cardiac toxicity following prior chemotherapy\n* History of neurological conditions\n* History of hemorrhagic or ischemic stroke within the last 6 months\n* History of cirrhotic liver disease\n* Previous clinical diagnosis of non-infectious pneumonitis\n* Prior hypersensitivity to monoclonal antibodies\n* Women who are pregnant or breast feeding\n* Carcinomatous meningitis, untreated central nervous system (CNS) disease or symptomatic CNS metastasis\n* History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment\n* Required used of folate-containing supplements (e.g. folate deficiency)\n* Has a known additional malignancy that is progressing or required active treatment within 3 years of first dose of study treatment",
    "miscellaneous_criteria": ""
}